Market Overview

QuintilesIMS Named to FORTUNE's 2017 List of "World's Most Admired Companies"


QuintilesIMS has once again been named to FORTUNE magazine's "World's Most Admired Companies" list. The 2017 listing, which was released earlier today, marks the third consecutive year the company has been recognized by FORTUNE as a most admired company.

QuintilesIMS received the distinction in FORTUNE's Healthcare: Pharmacy and Other Services category with high marks in quality of management, value as a long-term investment, effectiveness in conducting business globally and wise use of corporate assets.

"Being named to FORTUNE's list of the World's Most Admired Companies is evidence that both our peers and our clients understand the long term strategy and value our organization provides to our clients," said QuintilesIMS Chairman and CEO Ari Bousbib. "This honor is built upon the dedication and focus of our more than 50,000 employees around the world to create solutions that help our clients drive healthcare forward."

FORTUNE's World's Most Admired Companies list is the definitive report card on corporate reputations. Since 1997, FORTUNE has identified, selected and ranked the World's Most Admired Companies, uncovering the business practices that make these companies highly regarded among their peers.

Most Admired Company Survey Methodology

In compiling the Most Admired list, FORTUNE survey partner Korn Ferry Hay Group surveyed 680 companies from 28 countries asking executives, directors and analysts to rate companies within their own industry on nine reputation drivers considered to be crucial to a company's global success. These drivers include financial soundness, long-term investment value, people management, social responsibility, use of assets, quality of management, quality of products/services, innovation and global competitiveness. A company's score must rank in the top half of its industry survey to be listed.

About QuintilesIMS

QuintilesIMS (NYSE: Q) is a leading integrated information and technology-enabled healthcare service provider worldwide, dedicated to helping its clients improve their clinical, scientific and commercial results. Formed through the merger of Quintiles Transnational and IMS Health, QuintilesIMS's approximately 50,000 employees conduct operations in more than 100 countries. Companies seeking to improve real-world patient outcomes through treatment innovations, care provision and access can leverage QuintilesIMS's broad range of healthcare information, technology and service solutions to drive new insights and approaches. QuintilesIMS provides solutions that span clinical to commercial, bringing customers a unique opportunity to realize the full potential of innovations and advanced healthcare outcomes.

As a global leader in protecting individual patient privacy, QuintilesIMS uses healthcare data to deliver critical, real-world disease and treatment insights. Through a wide variety of privacy-enhancing technologies and safeguards, QuintilesIMS protects individual privacy while managing information to drive healthcare forward. These insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders in the development and approval of new therapies, and to identify unmet treatment needs and understand the safety, effectiveness and value of pharmaceutical products in improving overall health outcomes. To learn more, visit

Click here to subscribe to Mobile Alerts for QuintilesIMS.

Media Relations:
Phil Bridges, +1-919-998-1653
Mobile: +1-919-457-6347
Tor Constantino, +1-484-567-6732
Investor Relations:
Andrew Markwick, +1-973-257-7144

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at